## Abstract Atypical hemolytic uremic syndrome (aHUS) is a rare form of complement dysregulation disease, and recently various reports have shown that it is associated with one or more mutations in the complement regulatory genes including complement factor H (__CFH__). Plasma exchange is a therape
Cisplatin-associated hemolytic-uremic syndrome. Successful treatment with a staphylococcal protein A column
โ Scribed by Peter R. Watson; Troy H. Guthrie Jr.; Ralph J. Caruana
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 395 KB
- Volume
- 64
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Hemolytic uremic syndrome/thrombotic thrornbocytopenic purpura (HUSITTP) is a rare and often fatal complication of bonc marrow transplantation (BMT). In this study. wc rcport eight such cases (seven allo and onc auto) treated with plasma exchanges (PE), vincristine (six paticnts), and discontinuatio
We present a case of a patient who developed all manifestations of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) acutely following treatment of cutaneous T-cell lymphoma (CTCL, Sezary syndrome) with deoxycoformycin (pentostatin). Symptoms and signs included severe thrombocy
Many of the complement regulatory genes within the RCA cluster (1q32) have arisen through genomic duplication and the resulting high degree of sequence identity is likely to predispose to gene conversion events. The highest degree of identity is between the genes for factor H (CFH) and five factor H
Sensory or sensorimotor demyelinating polyneuropathies may be associated with monoclonal immunoglobulins (paraproteins). Our prior experience suggests that "off-line" Prosorba column treatments may be effective therapy for patients with polyneuropathies associated with paraproteins of the IgG class.